DOJ Files Against Regeneron for Inflated Drug Price Reporting

The Department of Justice (DOJ) filed a complaint under the False Claims Act (FCA) against Regeneron Pharmaceuticals alleging that the company knowingly submitted average sales price (ASP) reports to CMS that resulted in inflated Medicare reimbursements to the company.
Source: Drug Industry Daily